HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers.

Abstract
Gastrointestinal cancer causes countless deaths every year due to therapeutic resistance. However, whether metabolic alterations contribute to chemoresistance is not well understood. In this study, we report that fatty acid (FA) catabolism was activated in gastrointestinal cancer cells treated with oxaliplatin, which exhibited higher expression of the rate-limiting enzymes carnitine palmitoyltransferase 1B (CPT1B) and CPT2. The clinical analysis also showed that high expression of these enzymes was associated with poor oxaliplatin-based chemotherapy outcomes in patients. Furthermore, genetic or pharmacological inhibition of CPT2 with perhexiline disturbed NADPH and redox homeostasis and increased reactive oxygen species (ROS) generation and cell apoptosis in gastrointestinal cancer cells following oxaliplatin treatment. Specifically, the combination of oxaliplatin and perhexiline significantly suppressed the progression of gastrointestinal cancer in cell-based xenograft and patient-derived xenograft (PDX) models. Mechanistically, CPT2 was transcriptionally upregulated by nuclear factor of activated T cells 3 (NFATc3), which translocated to the nucleus in response to oxaliplatin treatment. In summary, our study suggests that the inhibition of CPT-mediated FA catabolism combined with conventional chemotherapy is a promising therapeutic strategy for patients with gastrointestinal cancers.
AuthorsYun Wang, Jia-Huan Lu, Feng Wang, Ying-Nan Wang, Ming-Ming He, Qi-Nian Wu, Yun-Xin Lu, Hong-En Yu, Zhan-Hong Chen, Qi Zhao, Jia Liu, Yan-Xing Chen, De-Shen Wang, Hui Sheng, Ze-Xian Liu, Zhao-Lei Zeng, Rui-Hua Xu, Huai-Qiang Ju
JournalCancer letters (Cancer Lett) Vol. 473 Pg. 74-89 (03 31 2020) ISSN: 1872-7980 [Electronic] Ireland
PMID31904482 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2019 The Author(s). Published by Elsevier B.V. All rights reserved.
Chemical References
  • Fatty Acids
  • NFATC Transcription Factors
  • NFATC3 protein, human
  • Reactive Oxygen Species
  • Oxaliplatin
  • NADP
  • CPT1B protein, human
  • Carnitine O-Palmitoyltransferase
  • Perhexiline
Topics
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology, therapeutic use)
  • Carcinogenesis (drug effects, pathology)
  • Carnitine O-Palmitoyltransferase (antagonists & inhibitors, metabolism)
  • Cell Line, Tumor
  • Colorectal Neoplasms (drug therapy, pathology)
  • Drug Synergism
  • Fatty Acids (metabolism)
  • Female
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Mice
  • NADP (metabolism)
  • NFATC Transcription Factors (metabolism)
  • Oxaliplatin (pharmacology, therapeutic use)
  • Perhexiline (pharmacology, therapeutic use)
  • Reactive Oxygen Species
  • Stomach Neoplasms (drug therapy, pathology)
  • Up-Regulation (drug effects)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: